Copyright © 2021 Turning Point Therapeutics, Inc. | All Rights Reserved | Terms of Use | Privacy Policy Statement
Pipeline
Our internally developed pipeline of next-generation tyrosine kinase inhibitors (TKIs) target genetic drivers of cancer in both TKI-naïve and TKI-pretreated patients. We hold development and commercialization rights to our drug candidates in all regions except repotrectinib in certain countries in Greater China.
¹ Partnered with Zai Lab in Greater China; Turning Point retains worldwide rights outside of Greater China. ² Turning Point retains worldwide rights.
Turning Point Therapeutics has been granted Breakthrough Therapy designation by the Food and Drug administration (FDA) for the treatment of patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC) who have not been treated with a ROS1 tyrosine kinase inhibitor (TKI-naïve). Repotrectinib has also been granted three Fast Track designations by the FDA in ROS1-positive NSCLC patients who are TKI-naïve, ROS1-positive NSCLC patients who have been previously treated with one prior platinum chemotherapy and one prior ROS1 TKI, and NTRK-positive patients with advanced solid tumors who have progressed following treatment with at least one prior line of chemotherapy and one or two prior TRK TKIs.